IGCASEHealthcare·Biotechnology#457 in industry

IGC Pharma, Inc.

+10.8% · 90d

$0.32

-0.02 (-4.69%)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

IGC Pharma, Inc. — 8-K Filing

IGCIGC Pharma, Inc.

# 🧾 What This Document Is This is an **8-K filing**, which is like a "breaking news" report a public company sends to the SEC to announce major events. This specific report announces a **new marketing partnership**. It's not about clinical trial results or financials, but about a strategic move to

Read summaryView on SEC EDGAR

Key Data

Market Cap$31.8M

Open$0.33

Prev Close$0.34

Day Range$0.32 – $0.34

52W Range$0.24 – $0.50

Volume394,346

P/E (TTM)—

EPS$-0.06

Dividend Yield—

Beta0.31

Revenue Growth-53.60%

Price Target$4.13(+1183.4%)

Analyst Ratings

Strong Buy2 analysts

Buy 2Hold 0Sell 0

About

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Healthcare · Biotechnology

70 employees

igcpharma.com